a Medica Scientia Innovation Research (MedSIR) , Barcelona , Spain.
b IOB Institute of Oncology, Quirónsalud Group , Madrid and Barcelona , Spain.
Expert Opin Drug Saf. 2019 May;18(5):347-355. doi: 10.1080/14740338.2019.1608946. Epub 2019 May 20.
: Eribulin mesylate is a highly potent anticancer agent approved for use in pretreated metastatic breast cancer (MBC). Clinical trials of eribulin in MBC have demonstrated activity against this tumor type, and a phase 3 study in patients with MBC previously treated with an anthracycline and a taxane showed a significant increase in overall survival (OS) with eribulin versus control regimens. : This review presents overviews of the development of eribulin, its pharmacology, and its efficacy in MBC. A detailed review of its safety profile is presented, and the safety of eribulin is compared with other agents commonly used to treat MBC. : As eribulin is the only drug shown to improve OS in patients with pretreated MBC, it is an important treatment option for many patients. Eribulin is currently considered a second-line (Europe) or third-line (United States) therapy, and studies have been examining use in the first-line setting. The use of eribulin in combination with other therapies is beginning to be explored because its manageable safety profile makes it an ideal combination-treatment partner. Emerging eribulin combination-treatment data suggest a manageable toxicity profile, and eribulin is set to be a key drug for the treatment of MBC in the future.
甲磺酸艾日布林是一种高效的抗癌药物，已被批准用于治疗转移性乳腺癌（MBC）。艾日布林在 MBC 中的临床试验显示了对这种肿瘤类型的活性，一项针对先前接受过蒽环类和紫杉类药物治疗的 MBC 患者的 3 期研究表明，与对照组相比，艾日布林显著增加了总生存期（OS）。
本文综述了艾日布林的开发、药理学及其在 MBC 中的疗效。详细介绍了其安全性概况，并将艾日布林的安全性与其他常用于治疗 MBC 的药物进行了比较。
由于艾日布林是唯一被证明能改善预处理 MBC 患者 OS 的药物，因此它是许多患者的重要治疗选择。艾日布林目前被认为是二线（欧洲）或三线（美国）治疗药物，并且已经开始研究在一线治疗中的应用。由于其可管理的安全性特征，艾日布林与其他疗法联合使用的情况开始得到探索，因为它是一种理想的联合治疗伙伴。正在出现的艾日布林联合治疗数据表明其毒性特征具有可控性，艾日布林有望成为未来治疗 MBC 的关键药物。
